Journal
IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA
Volume 31, Issue 2, Pages 311-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.iac.2011.03.005
Keywords
Allergen immunotherapy; IgE-mediated allergy; IgE-facilitated allergen binding; IgG4; IgE-blocking factor
Categories
Funding
- Immune Tolerance Network
- National Institutes of Health USA
- Biotechnology and Biologic Sciences Research Council UK (BBSRC)
- ALK-Abello
- Horsholm, Denmark
- Medical Research Council [G1000758, G1000758B] Funding Source: researchfish
- National Institute for Health Research [NF-SI-0508-10212] Funding Source: researchfish
Ask authors/readers for more resources
Allergen immunotherapy is an effective treatment option in patients with IgE-mediated allergy, particularly in those who do not respond to usual antiallergic drugs. Successful immunotherapy has been associated with the suppression of allergic inflammation in target organs and increases in allergen-specific IgG antibodies, particularly the IgG(4) subclass. To date there are no biomarkers that are predictive of the clinical response to immunotherapy. This article explores the possibility that functional assays based on the ability of IgG to compete with IgE and inhibit IgE-allergen complex formation may be surrogate or predictive of the clinical response to immunotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
